Press release

by admin

ATLANTA, Nov. 16, 2015 / — Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that a new analysis of patients from the FAME™ Study demonstrated a significant slowing of the progression of diabetic retinopathy (DR) in patients with diabetic macular edema (DME) treated with ILUVIEN®.
“Analysis of Diabetic Retinopathy Progression in Patients Treated with 0.2 micrograms/day Fluocinolone Acetonide Over 36 Months” was presented by Charles C. Wykoff, M.D., Ph.D., Retina Consultants ofHouston, as a Late Breaking Development during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting 2015 in Las Vegas. In this analysis, continuous, low dose therapy with ILUVIEN (0.2 micrograms/day Fluocinolone Acetonide) in the FAME Study was evaluated to determine its effect on progression to proliferative diabetic retinopathy (PDR), and the worsening of PDR, in DME patients. Along with the development of DME, these represent the most clinically significant measures of worsening of DR.
At month 36, statistically significantly fewer ILUVIEN-treated eyes experienced progression of PDR (17%) versus sham-treated eyes (31%) (p<0.001). Progression of PDR in the FAME Study was determined based on fundus photographs that were graded by a masked, certified reading center, and by the incidence of the use of pan-retinal photocoagulation and the incidence of vitrectomy to treat PDR.
“The data demonstrate an important clinical benefit from continuous, low-dose corticosteroid therapy provided by ILUVIEN,” said Dr. Wykoff. “From the physician’s perspective, being able to treat diabetic retinopathy in patients with DME with one injection is exciting. This important development demonstrates the therapeutic benefit of the continuous, multi-year treatment delivered by ILUVIEN.”
“We believe these results demonstrate the potential for ILUVIEN to significantly slow the progression of diabetic retinopathy,” said Dan Myers, Alimera president and chief executive officer. “This type of disease modifying effect has only been reported for anti-VEGF therapy when administered monthly over a multi-year period. Achieving this effect with ILUVIEN represents a significant benefit which we believe will extend to actual clinical practice and to patients.”……….
Read more:
Source: Blackbird PR News
Image: Iluvien®